Reda Garidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reda Garidi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdenour Ouikene
Department of Oncology-Hematology, Centre Hospitalier de Saint-Quentin, 1 Av. Michel de l’Hospital BP 608, 02321 Saint-Quentin, France
1 shared publication - Agnes Galez
Department of Oto-Rhino-Laryngology, Centre Hospitalier de Saint-Quentin, 02321 Saint-Quentin, France
1 shared publication - Alexandre Cau
Department of Pharmacy, Centre Hospitalier de Saint-Quentin, 02321 Saint-Quentin, France
1 shared publication Assia Alem
Service d'Oncologie et Hématologie, Centre Hospitalier de Saint-Quentin, 1 Avenue Michel de l'Hospital, Saint-Quentin 02100, France
1 shared publication- Bruno Chauffert
Department of Onco-hematology. Centre Hospitalier de Saint Quentin. 02321 Saint Quentin, France
1 shared publication Chahrazad Benchouk
Service d'Oncologie et Hématologie, Centre Hospitalier de Saint-Quentin, 1 Avenue Michel de l'Hospital, Saint-Quentin 02100, France
1 shared publication
Latest Publications
- Open Access
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5694
Successful Treatment of an Advanced Larynx Carcinoma Using Neo-Adjuvant Chemo-Immunotherapy and Cisplatin/Radiotherapy for a Patient with Rendu–Osler Disease
Background/Objectives: Rendu–Osler disease is a rare genetic disease, characterized by widespread telangiectasia that can involve the skin and mucous membranes. The diagnosis is based on spontaneous and recurrent epistaxis; various mucosal and cutaneous telangiectasia at typical sites; visceral manifestations including gastrointestinal telangiectasia or pulmonary, cerebral, or hepatic arteriovenous malformation; and a first-degree relative with hereditary hemorrhagic telangiectasia. Squamous cell carcinoma of the larynx generally develops in patients with a smoking history. It is most often treated by surgery and/or radiotherapy. To our knowledge, these two entities were never reported in the same patient. Methods: We herein report a case of a 51-year-old man with Rendu–Osler disease. He was subsequently diagnosed with a locally advanced well-differentiated squamous cell carcinoma of the vocal cord. Results: The patient received a neo-adjuvant chemo-immunotherapy, with nine weekly injections of paclitaxel (60 mg/m2/week), cisplatin (30 mg/m2/week), and cetuximab (250 mg/m2/week), and three injections of pembrolizumab (200 mg every 3 weeks). This controlled tumor bleeding, and then cisplatin-enhanced radiotherapy helped obtain a complete remission. Conclusions: Locally advanced squamous cell carcinoma of the larynx treatment in the context of active Rendu–Osler disease is challenging. If the wide curative surgical approach is deemed too risky, neo-adjuvant chemo-immunotherapy may present a helpful alternative as it may enhance the conditions in order to perform classical radiotherapy with concomitant cisplatin.
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5694
Open AccessSuccessful Treatment of an Advanced Larynx Carcinoma Using Neo-Adjuvant Chemo-Immunotherapy and Cisplatin/Radiotherapy for a Patient with Rendu–Osler Disease
Background/Objectives: Rendu–Osler disease is a rare genetic disease, characterized by widespread telangiectasia that can involve the skin and mucous membranes. The diagnosis is based on spontaneous and recurrent epistaxis; various mucosal and cutaneous telangiectasia at typical sites; visceral manifestations including gastrointestinal telangiectasia or pulmonary, cerebral, or hepatic arteriovenous malformation; and a first-degree relative with hereditary hemorrhagic telangiectasia. Squamous cell carcinoma of the larynx generally develops in patients with a smoking history. It is most often treated by surgery and/or radiotherapy. To our knowledge, these two entities were never reported in the same patient. Methods: We herein report a case of a 51-year-old man with Rendu–Osler disease. He was subsequently diagnosed with a locally advanced well-differentiated squamous cell carcinoma of the vocal cord. Results: The patient received a neo-adjuvant chemo-immunotherapy, with nine weekly injections of paclitaxel (60 mg/m2/week), cisplatin (30 mg/m2/week), and cetuximab (250 mg/m2/week), and three injections of pembrolizumab (200 mg every 3 weeks). This controlled tumor bleeding, and then cisplatin-enhanced radiotherapy helped obtain a complete remission. Conclusions: Locally advanced squamous cell carcinoma of the larynx treatment in the context of active Rendu–Osler disease is challenging. If the wide curative surgical approach is deemed too risky, neo-adjuvant chemo-immunotherapy may present a helpful alternative as it may enhance the conditions in order to perform classical radiotherapy with concomitant cisplatin.
- 19 May 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 73 (3) , 103520
Anthracycline and arsenic trioxide-based regimens for the treatment of acute promyelocytic leukemia: thiamine levels monitoring importance
- 19 May 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 73 (3) , 103520
Anthracycline and arsenic trioxide-based regimens for the treatment of acute promyelocytic leukemia: thiamine levels monitoring importance